α-Lactalbumin forms the regulatory subunit of the lactose synthase (LS) heterodimer and β-1,4-galactosyltransferase (beta4Gal-T1) forms the catalytic component. Together, these proteins enable LS to produce lactose by transferring galactose moieties to glucose. As a multimer, alpha-lactalbumin strongly binds calcium and zinc ions and may possess bactericidal or antitumor activity. A folding variant of human alpha-lactalbumin that may form in acidic environments such as the stomach, called HAMLET, probably induces apoptosis in tumor and immature cells.
Research by a Dr. Vincent Tuohy at the Cleveland Clinic is using α-Lactalbumin as the basis for a potential breast cancer vaccine. Breast cancer usually develops later in life, well after the typical child-bearing age. This protein is normally expressed only during late pregnancy and lactation, but Tuohy notes that expression is also common in newly formed tumours: “One of the things they do is make inappropriate proteins like α-lactalbumin". Dr. Tuohy's group has developed a vaccine that targets α-Lactalbumin, tricking the patient's own immune system to attack breast tissue that expresses the α-Lactalbumin genes and thus killing a high percentage of the cancerous cells. In fact, vaccinated mice achieved 100% protection against breast cancer, provided they were dosed before tumours began to develop. Tissue damage and inflammation were limited to the breast tissue of nursing animals. This should not be a problem for humans, as the highest risk breast cancer patients are generally past childbearing age.
The molecular weight is 14178 Da, and the isoelectric point is between 4.2 and 4.5. One of the main structural differences with beta-lactoglobulin is that it does not have any free thiol group that can serve as the starting-point for a covalent aggregation reaction. As a result, pure α-lactalbumin will not form gels upon denaturation and acidification.
The sequence comparison of α-lactalbumin shows a strong similarity to that of lysozymes, specifically the Ca2+-binding c-lysozyme. So the expected evolutionary history is that gene duplication of the c-lysozyme was followed by mutation. This gene predates the last common ancestor of mammals and birds, which probably puts its origin at about 300 Ma.
^Kleinberg JL, Todd J, Babitsky G (1983). "Inhibition by estradiol of the lactogenic effect of prolactin in primate mammary tissue: reversal by antiestrogens LY 156758 and tamoxifen.". PNAS80 (13): 4144–4148. doi:10.1073/pnas.80.13.4144. PMC394217. PMID97356016.
^Acharya KR, Stuart DI, Walker NP, Lewis M, Phillips DC (1989). "Refined structure of baboon alpha-lactalbumin at 1.7 A resolution. Comparison with C-type lysozyme". J. Mol. Biol.208 (1): 99–127. doi:10.1016/0022-2836(89)90091-0. PMID2769757.
Hall L, Craig RK, Edbrooke MR, Campbell PN (1982). "Comparison of the nucleotide sequence of cloned human and guinea-pig pre-alpha-lactalbumin cDNA with that of chick pre-lysozyme cDNA suggests evolution from a common ancestral gene.". Nucleic Acids Res.10 (11): 3503–3515. doi:10.1093/nar/10.11.3503. PMC320727. PMID6285305.
Stacey A, Schnieke A, Kerr M, et al. (1995). "Lactation is disrupted by alpha-lactalbumin deficiency and can be restored by human alpha-lactalbumin gene replacement in mice.". Proc. Natl. Acad. Sci. U.S.A.92 (7): 2835–2839. doi:10.1073/pnas.92.7.2835. PMC42313. PMID7708733.
Lindner RA, Kapur A, Carver JA (1997). "The interaction of the molecular chaperone, alpha-crystallin, with molten globule states of bovine alpha-lactalbumin.". J. Biol. Chem.272 (44): 27722–9. doi:10.1074/jbc.272.44.27722. PMID9346914.
Giuffrida MG, Cavaletto M, Giunta C, et al. (1998). "The unusual amino acid triplet Asn-Ile-Cys is a glycosylation consensus site in human alpha-lactalbumin.". J. Protein Chem.16 (8): 747–53. doi:10.1023/A:1026359715821. PMID9365923.
Chandra N, Brew K, Acharya KR (1998). "Structural evidence for the presence of a secondary calcium binding site in human alpha-lactalbumin.". Biochemistry37 (14): 4767–4772. doi:10.1021/bi973000t. PMID9537992.
Håkansson A, Andréasson J, Zhivotovsky B, et al. (1999). "Multimeric alpha-lactalbumin from human milk induces apoptosis through a direct effect on cell nuclei.". Exp. Cell Res.246 (2): 451–60. doi:10.1006/excr.1998.4265. PMID9925761.
Svensson M, Sabharwal H, Håkansson A, et al. (1999). "Molecular characterization of alpha-lactalbumin folding variants that induce apoptosis in tumor cells.". J. Biol. Chem.274 (10): 6388–6396. doi:10.1074/jbc.274.10.6388. PMID10037730.
Harata K, Abe Y, Muraki M (1999). "Crystallographic evaluation of internal motion of human alpha-lactalbumin refined by full-matrix least-squares method.". J. Mol. Biol.287 (2): 347–58. doi:10.1006/jmbi.1999.2598. PMID10080897.
Last AM, Schulman BA, Robinson CV, Redfield C (2001). "Probing subtle differences in the hydrogen exchange behavior of variants of the human alpha-lactalbumin molten globule using mass spectrometry.". J. Mol. Biol.311 (4): 909–19. doi:10.1006/jmbi.2001.4911. PMID11518539.
Andrews P (1970). "Purification of lactose synthetase a protein from human milk and demonstration of its interaction with alpha-lactalbumin.". FEBS Letters9 (5): 297–300. doi:10.1016/0014-5793(70)80382-9. PMID11947697.